MedPath

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Not Applicable
Recruiting
Conditions
Insulin Sensitivity
Insulin Resistance
Long COVID
Registration Number
NCT05833217
Lead Sponsor
Stanford University
Brief Summary

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
55
Inclusion Criteria
  • Ages 18 to 80
  • BMI ≥ 25 kg/m2
  • not currently pregnant
Exclusion Criteria

Arm 2 (Adipose Tissue Biopsy) exclusions include

  • pregnancy
  • prior liposuction
  • recent change in weight (> 2 kg in one month)
  • bleeding disorders
  • anticoagulant use

Arm 3 (healthy controls only) exclusions include patients with

  • major organ disease
  • diabetes
  • history of liposuction
  • bariatric surgery
  • eating disorders
  • psychiatric disorders
  • pregnancy or lactation
  • recent change in weight (over the past 12 weeks),
  • use of weight loss medication or oral steroids
  • hematocrit < 33%
  • fasting glucose >= 126 mg/dL
  • blood pressure >160/100 mmHg

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Triglyceride/HDL-cholesterol ratio2 years

Investigate the relationship between insulin resistance, as described by triglyceride/HDL-cholesterol ratio, and incident PASC (long COVID).

Concentration of Viral RNA in Adipose Tissue2 years

Investigate the expression of viral RNA in adipose tissue in response to COVID-19 infection. Compare adipose tissue transcripts such as known MODY transcription factors measured by PCR between COVID-19 infected participants and healthy controls.

Rate of Inflammatory Response2 years

Investigate inflammatory response to PPARgamma agonist (drug) and other compounds tested in vitro in human fat cells. Compare plasma inflammatory cytokine levels in serum samples as measured by Luminex immunoassay between participants identified as Insulin Sensitive (IS) and Insulin Resistant (IR) using the 2-stage Steady State Plasma Glucose test.

Rate of Inflammatory Gene Expression in Adipose Tissue2 years

Investigate the expression of inflammatory genes in adipose tissue in response to COVID-19 infection. Compare adipose tissue transcripts such as defensin chemokine receptors and platelet activation factors measured by PCR between COVID-19 infected participants and healthy controls.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Clinical and Translational Research Unit

🇺🇸

Palo Alto, California, United States

Stanford Health

🇺🇸

Palo Alto, California, United States

Clinical and Translational Research Unit
🇺🇸Palo Alto, California, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.